NAGE earnings call: key takeaways

• Niagen Bioscience reported revenue of $27.2 million for the third quarter of 2026, with EPS not provided, but the company highlighted strong cash flow and a debt-free balance sheet (14:44)
• The call emphasized continued investment in growth areas like Niagen Plus and pharmaceutical development. (14:44)

Results vs expectations

What changed since last quarter

• The company raised guidance for fourth quarter revenue, expecting improvement from the third quarter. (14:44)
• The CFO emphasized 2026 as an investment year leading to growth in 2027 and beyond. (14:44)
• The CEO mentioned the potential for NB4168 to generate significant value through rare disease approvals and FDA voucher programs. (17:58)

What analysts pressed on

• Whether the new lower-cost salt form will be used in supplements or only the ingredients business. (29:13)
• Concerns about the impact of litigation costs on future SG&A expenses. (27:09)
• Questions about the potential size and duration of the Mass General study on Niagen's effects. (23:46)

In their words

• We generated positive adjusted EBITDA and operating cash flow, increased our cash balance to $69.5 million, and maintained a debt-free balance. (14:44)
• We believe it can be manufactured at significantly lower cost, with the potential to materially reduce cost of goods... Robert Fried (4:20)